tiprankstipranks
Trending News
More News >
Jagsonpal Pharmaceuticals Ltd. (IN:JAGSNPHARM)
:JAGSNPHARM
India Market
Advertisement

Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

JAGSNPHARM Financial Forecast

JAGSNPHARM Earnings Forecast

The previous quarter’s earnings for JAGSNPHARM were ₹1.62.
The previous quarter’s earnings for JAGSNPHARM were ₹1.62.

JAGSNPHARM Sales Forecast

The previous quarter’s earnings for JAGSNPHARM were ₹756.12M.
The previous quarter’s earnings for JAGSNPHARM were ₹756.12M.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:JAGSNPHARM
TR | OpenAI - 4o
TR | OpenAI - 4o
₹264₹262
Hold
22.17%
Upside
Reiterated
09/23/25
AI Generated ArticleAI Generated Article
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:JAGSNPHARM
TR | OpenAI - 4o
TR | OpenAI - 4o
₹264₹262
Hold
22.17%
Upside
Reiterated
09/23/25
AI Generated ArticleAI Generated Article
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

JAGSNPHARM Analyst Recommendation Trends

Rating
Jul 25
Sep 25
Strong Buy
0
0
Buy
7
7
Hold
0
4
Sell
0
0
Strong Sell
0
0
total
7
11
In the current month, JAGSNPHARM has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. JAGSNPHARM average Analyst price target in the past 3 months is 262.00.
Each month's total comprises the sum of three months' worth of ratings.

JAGSNPHARM Stock Forecast FAQ

What is IN:JAGSNPHARM’s average 12-month price target, according to analysts?
Based on analyst ratings, Jagsonpal Pharmaceuticals Ltd.’s 12-month average price target is 262.00.
    What is IN:JAGSNPHARM’s upside potential, based on the analysts’ average price target?
    Jagsonpal Pharmaceuticals Ltd. has 22.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Jagsonpal Pharmaceuticals Ltd. a Buy, Sell or Hold?
          Jagsonpal Pharmaceuticals Ltd. has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Jagsonpal Pharmaceuticals Ltd.’s share price target?
            The average share price target for Jagsonpal Pharmaceuticals Ltd. is 262.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹262.00 ,and the lowest forecast is ₹262.00. The average share price target represents 22.17% Increase from the current price of ₹214.45.
              What do analysts say about Jagsonpal Pharmaceuticals Ltd.?
              Jagsonpal Pharmaceuticals Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of Jagsonpal Pharmaceuticals Ltd.?
                To buy shares of IN:JAGSNPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis